Valbiotis SA (FR:ALVAL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Valbiotis announced the success of its INSIGHT clinical study, demonstrating that TOTUM•854 significantly reduces systolic blood pressure in individuals with untreated mild hypertension. This success marks TOTUM•854 as a promising non-drug solution for cardiovascular disease prevention, aligning with Valbiotis’ mission to improve health through innovative plant-based products.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.